Method for the treatment of inflammatory disorders
View Patent ↗A method for the treatment of inflammatory disorders is disclosed, particularly the treatment of arthritis. The method comprises the administration of a function blocking antibody which is capable of binding an epitope of VLA-1.
1. A method for the treatment of arthritis comprising administering to a subject suffering from arthritis a function blocking antibody, or function blocking antibody fragment, which binds to a VLA-1 epitope consisting of the amino acids Val-Gln-Arg-Gly-Gly-Arg (SEQ ID NO: 8), wherein a dosage of about 0.1 mg/kg/day to about 10 mg/kg/day of the antibody or antibody fragment is administered to the subject.
2. A method according to claim 1 wherein the decrease in arthritic score is about 65% or greater.
3. A method of claim 1 , wherein the decrease in arthritic score is about 79% or greater.
4. A method according to claim 1 wherein the decrease in arthritic score is about 85% or greater.
5. A method according to claim 1 wherein the decrease in arthritic score is about 90% or greater.
6. A method according to claim 1 , wherein the antibody is monoclonal.
7. A method according to claim 1 , wherein the subject is a human.
8. A method according to claim 1 , wherein the subject suffers from rheumatoid arthritis.
9. A method of claim 1 , wherein the antibody or antibody fragment is administered subcutaneously.
10. A method of claim 1 , wherein the subject is a human.
11. A method of claim 1 , wherein the antibody or antibody fragment is administered to the subject in an amount of between about 0.3 mg/kg/day to about 1 mg/kg/day.
12. A method of claim 1 , wherein the antibody or antibody fragment is administered to the subject at intervals of every one to 14 days.
13. A method for the treatment of arthritis comprising administering to a subject suffering from arthritis a function blocking antibody, or function blocking antibody fragment, which binds to a VLA-1 epitope consisting of the amino acids Val-Gln-Arg-Gly-Gly-Arg (SEQ ID NO: 8), wherein a dosage of about 5 mg/kg/day to about 12.5 mg/kg/day of the antibody or antibody fragment is administered to the subject.